Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb412 Monoclonal Bispecific Antibody · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: Active Drug | ACTIVE_COMPARATOR | Active XmAb412 to be administered to healthy adult participants. |
| Part A: Placebo | PLACEBO_COMPARATOR | Placebo Comparator to be administered to healthy participants. |
| Part B: Active | ACTIVE_COMPARATOR | Active XmAb412 to be administered to healthy participants. |
| Part B: Placebo | PLACEBO_COMPARATOR | Placebo Comparator to be administered to healthy participants. |
| Name | Type | Description |
|---|---|---|
| XmAb412 Monoclonal Bispecific Antibody | DRUG | Monoclonal Bispecific Antibody |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Age 18-55 years old * Must be in good health with no significant medical history * BMI 18-35 kg/m2 * Contraceptive use consistent with local regulations * Able and willing to provide written informed consent Exclusion Criteria: * Any physical condition that prohibits study c...
XmAb412 is an investigational monoclonal bispecific antibody being studied in healthy adult participants. It is currently in Phase 1 clinical development, with an active trial evaluating its safety and tolerability. The drug is not approved for any indication and is not being studied in any patient population at this time.
XmAb412 is being developed by Xencor, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol XNCR. Xencor is conducting a Phase 1 clinical trial of XmAb412 in healthy participants, with the study currently recruiting in Australia.
XmAb412 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. A single Phase 1 trial is currently recruiting healthy adult participants to evaluate the drug, with an enrollment target of 128 participants.
XmAb412 is being studied in one active clinical trial, identified as NCT07713485, titled "Study of XmAb412 in Healthy Participants." This Phase 1, randomized, double-blind, placebo-controlled trial is recruiting 128 healthy adult participants aged 18 years and older in Australia.
XmAb412 is a monoclonal bispecific antibody, which is a biologic drug, not a small molecule. It is being developed by Xencor, Inc. and is currently in Phase 1 clinical testing in healthy volunteers. The drug is investigational and has not been approved for any use.
XmAb412 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The ongoing trial, NCT07713485, is studying the drug in healthy adult participants to assess its safety and tolerability, and it has not yet progressed to later-stage trials or regulatory review.